Cytox Limited is a UK-based company with a unique scientific and proprietary technology platform. Through the application of this fundamental science and our specific know-how, we are elucidating the biology and genetics behind dementia, as well as developing prognostics tests for cognitive decline and individual risk of developing AD or other dementias.
Contact us to find out more about our plans and how you could work with us.
The business and science team is supported by an experienced Board of Directors:
Dr Richard Pither, CEO
Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s disease patients.
Dr Zsuzsanna Nagy, Science Director
Dr Nagy is well known for her ground-breaking work on the involvement of the cell cycle in neurodegenerative diseases. For over 20 years she has been working on the pathogenic mechanisms of Alzheimer’s disease, novel biomarker development and early stage drug discovery for disease-modifying drugs. She is Senior Lecturer and Lead of the Neurodegeneration and Repair team in the Dept of Neuropharmacology and Neurobiology, Birmingham University.
Dr Andrew Carr, Chairman
Andrew has already worked with Cytox in an advisory capacity and brings a wealth of highly relevant experience from both large companies (Amersham Biosciences; GE Healthcare; Thermo Fisher Scientific) and smaller biotechs (Teraview; deltaDOT; Akubio, BAC B.V).